TrialClinical therapeutics2022

Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.

Mohsen Nafar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.